Catalyst Pharmaceuticals, Inc. (CPRX)

Market Cap	3.00B
Revenue (ttm)	491.73M
Net Income (ttm)	163.89M
Shares Out	121.45M
EPS (ttm)	1.31
PE Ratio	18.85
Forward PE	17.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	894,624
Open	24.90
Previous Close	24.84
Day's Range	24.27 - 24.97
52-Week Range	14.47 - 26.16
Beta	0.84
Analysts	Strong Buy
Price Target	32.50 (+31.63%)
Earnings Date	May 7, 2025

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2006
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: CPRX
• Website: https://catalystpharma.com

Financial Performance

In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.

Analyst Forecast

According to 8 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price forecast is $32.5, which is an increase of 31.63% from the latest price.

Price Target

$32.5

(31.63% upside)

Analyst Consensus: Strong Buy